FGFR2 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
FGFR2 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This FGFR2 target evaluation report is generated based on structured data from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP. It turns target biology, disease context, clinical validation, competitive intensity, and IP strategy into a repeatable target evaluation workflow for life sciences AI agents.
Explore PatSnap Life Sciences MCP Servers
Target FGFR2 UniProt P21802 | Target-linked drugs 154 111 active development drugs | Cholangiocarcinoma trials 109 FGFR2 + cholangiocarcinoma MCP query | Released results 101 Clinical result query |
Executive View
FGFR2 is a precision-oncology target with strong relevance in cholangiocarcinoma, especially FGFR2 fusion or rearrangement biology. The opportunity is attractive, but competition and resistance biology require clear differentiation in mutation coverage, selectivity, safety, sequencing, and combination strategy.
- Biology: Target & Disease MCP identifies FGFR2 as a receptor tyrosine kinase regulating proliferation, differentiation, migration, apoptosis, and MAPK/AKT signaling.
- Disease context: Cholangiocarcinoma/bile duct neoplasms are tumors or cancer of the bile ducts, with 144 development drugs in the disease record.
- Validation: Clinical Trials MCP returns 109 FGFR2 + Cholangiocarcinoma trials and 101 released result records.
- Strategy: Differentiate by FGFR2 fusion detection, resistance mutation coverage, selectivity, tolerability, and perioperative or combination use.
Scorecard
Biology confidence: High
Clinical validation: High precision-oncology signal
Competitive pressure: High
White-space potential: Resistance and sequencing-led
Biology and Disease Rationale
Target & Disease MCP returns FGFR2 with UniProt P21802, 154 target-linked drugs, and 111 active development drugs. The target profile describes FGFR2 as a cell-surface receptor tyrosine kinase that regulates proliferation, differentiation, migration, apoptosis, and signaling through PLCG1, FRS2, RAS/MAPK, and AKT pathways.
For bile duct neoplasms/cholangiocarcinoma, Target & Disease MCP describes tumors or cancer of the bile ducts. The disease record shows 144 development drugs and 212 roll-up development drugs, making biomarker-led development and resistance management essential.
Explore PatSnap Life Sciences MCP Servers for AI agents
Selected Trial and Result Evidence
| OPTIC trial: durvalumab/cisplatin/gemcitabine +/- futibatinib Clinical Trials MCP returned a not-yet-recruiting Phase 2 preoperative study in resectable intrahepatic cholangiocarcinoma. |
| Tinengotinib hepatic impairment PK study Ongoing Phase 1 study in participants with hepatic impairment and normal hepatic function, relevant to hepatobiliary development practicality. |
| Lirafugratinib Phase 2 result Clinical trial result query returned a positive Phase 2 record in FGFR2 fusion or rearrangement solid tumors. |
| Lenvatinib plus immunotherapy combinations Released positive Phase 2 cholangiocarcinoma records for lenvatinib-based combination strategies, underscoring broader competitive pressure around targeted and immune combinations. |
IP and R&D Recommendation
FGFR2 IP review should map kinase inhibitor chemotypes, FGFR2 fusion/rearrangement claims, resistance mutation coverage, dosing with hepatic impairment, combination claims with chemotherapy or immunotherapy, and companion diagnostic/NGS selection strategies.
Recommendation
FGFR2 is attractive when the program has a clear precision-oncology edge. The strongest strategy is improved resistance coverage, better tolerability, biomarker-defined enrollment, or a credible perioperative/combination plan in cholangiocarcinoma.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
Data note: Target biology, disease profile, clinical trial counts, trial examples, and result evidence were generated from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP queries performed on July 9, 2026.
